糖尿病患者与非糖尿病患者需要心力衰竭的心脏再同步治疗的结果:元分析
Aman Goyal1,2, Muhammad Daoud Tariq3, Abdul Moiz Khan4
1Department of Internal Medicine, Seth GS Medical College and KEM Hospital, Mumbai, India.
Heart rhythm O2
|July 28, 2025
概括
接受心脏再同步治疗 (CRT) 的糖尿病患者因所有原因和心血管事件死亡的风险更高. 这凸显了对这些患者个性化治疗策略的需要.
科学领域:
- 心脏病学 心脏病学
- 糖尿病学 糖尿病学
- 医疗技术 医疗技术 医学技术
背景情况:
- 心力衰竭 (HF) 影响全球数以百万计的人,心脏再同步治疗 (CRT) 改善了电动失同症患者的结果.
- 由于糖尿病相关的复杂性,CRT在患有HF的糖尿病患者中的有效性尚未得到充分确立.
研究的目的:
- 评估糖尿病对心力衰竭 (HF) 患者心脏再同步治疗 (CRT) 结果的影响.
- 为了比较糖尿病和非糖尿病HF人群之间的CRT的有效性和安全性.
主要方法:
- 对13项包括20073名参与者在内的观察性研究进行了元分析.
- 聚合风险比率 (RRs) 和平均差异是使用随机效应模型与95%置信区间计算的.
主要成果:
- 与非糖尿病患者相比,糖尿病患者的全因死亡风险 (RR 1.34) 和心血管死亡风险 (RR 1.49) 显著增加.
- 两组之间在中风,心肌梗塞的风险或左心室体积和射出分数的变化方面没有发现显著差异.
结论:
- 接受CRT的糖尿病患者经历了全因和心血管死亡率的增加.
- 这些发现强调了定制治疗策略的必要性,以及在糖尿病高风患者中仔细考虑CRT.
相关概念视频
Cardiomyopathy II: Dilated Cardiomyopathy
23
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
23
Heart Failure V: Medical Management
25
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
25
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
510
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
510
Heart Failure VI: Adjunct Therapies
28
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
28
Cardiomyopathy V: Interprofessional Care
34
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
34
Heart Failure Drugs: Inotropic Agents
728
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
728


